Study S003327

A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD9550 and AZD6234

ClinicalTrials.gov record

Registration

Registration: NCT07546760
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: RECRUITING
Enrollment: 28
Start: 2026-03-20
Primary completion: 2027-02-04
Lead sponsor: AstraZeneca
Conditions: Hepatic Impairment
Interventions: DRUG:AZD6234; DRUG:AZD9550
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

PK parameters AUCinf [Day 0 through Day 56]
PK parameters AUClast [Day 0 through Day 56]
PK parameters Cmax [Day 0 through Day 56]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.